Clinical trials: Ipilimumab, completed
Melanoma, Unresectable (Stage III) Melanoma
RTA 408 Capsules in Patients With Melanoma - REVEAL
Malignant melanoma is a leading cause of death from cutaneous malignancies, accounting for approximately three-fourths of all skin cancer deaths.
- Conditions
- Melanoma, Unresectable (Stage III) Melanoma, Metastatic (Stage IV) Melanoma
- Trial name
- NCT02259231
- Testing
- Omaveloxolone Capsules (2.5 mg/capsule), Ipilimumab (3 mg/kg), Nivolumab (240 mg)
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Biogen
Melanoma
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.
- Trial name
- NCT00623766
- Testing
- Ipilimumab, Corticosteroid: Betamethasone, Corticosteroid: Dexamethasone
- Where
- 14 sites in United States
- Volunteers
- 99 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
This study will evaluate the safety and efficacy of 2 different dosing schedules of pembrolizumab (MK-3475), every 2 weeks (Q2W) and every 3 weeks (Q3W), and compare the 2 schedules to treatment with ipilimumab in…
- Trial name
- NCT01866319
- Testing
- Pembrolizumab, Ipilimumab
- Volunteers
- 834 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer, Gastroesophageal Junction Cancer
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
- Trial name
- CheckMate649 (NCT02872116)
- Testing
- Nivolumab, Ipilimumab, Oxaliplatin
- Where
- 179 sites in United States, Argentina and 27 more
- Volunteers
- 2,031 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the return of cancer in patients who have had a…
- Trial name
- CheckMate 915 (NCT03068455)
- Testing
- nivolumab, ipilimumab
- Where
- 124 sites in United States, Australia and 17 more
- Volunteers
- 1,844 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment.
- Trial name
- NCT00162123
- Testing
- Ipilimumab
- Where
- 58 sites in United States, Argentina and 16 more
- Volunteers
- 248 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- CheckMate 650 (NCT02985957)
- Testing
- Nivolumab, Ipilimumab, Cabazitaxel
- Where
- 59 sites in United States, Australia and 8 more
- Volunteers
- 351 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
The primary objectives of the study are to determine the safety and activity of multiple doses of MDX-010 in patients with hormone-refractory prostate cancer (HRPC), and to determine the safety and activity profile of a single…
- Trial name
- NCT00050596
- Testing
- MDX-010 / MDX-010 + Docetaxel
- Where
- 11 sites in United States
- Sponsor
- Bristol-Myers Squibb
Melanoma
A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
The purpose of this study is to determine whether Ipilimumab will extend the life of chinese patients with Chemotherapy Naive Stage IV Melanoma more than Dacarbazine as well as to examine safety in this patient population.
- Trial name
- NCT02545075
- Testing
- Ipilimumab, Dacarbazine
- Where
- 8 sites in China
- Volunteers
- 182 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer (NSCLC)
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin
The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the life of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.
- Trial name
- NCT02279732
- Testing
- Paclitaxel, Carboplatin, Ipilimumab
- Where
- 49 sites in China, Germany and 4 more
- Volunteers
- 342 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer (NSCLC)
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally…
- Trial name
- CheckMate73L (NCT04026412)
- Testing
- nivolumab, ipilimumab, durvalumab
- Where
- 183 sites in United States, Argentina and 25 more
- Volunteers
- 925 people
- Sponsor
- Bristol-Myers Squibb
Advanced or Metastatic Solid Malignancies
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies
- Trial name
- NCT04887870
- Testing
- Sitravatinib, Nivolumab, Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 49 people
- Sponsor
- Mirati Therapeutics Inc.
Melanoma
Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases
The research questions to be addressed by this study are as follows: 1. What is the prevalence of ipilimumab use among adults with a history of autoimmune disease that received treatment with ipilimumab for advanced melanoma? 2.
- Trial name
- NCT02739386
- Testing
- Ipilimumab
- Where
- United States
- Volunteers
- 370 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer, Small Cell Lung Cancer
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
The purpose of the study is to determine whether ipilimumab given with paclitaxel/carboplatin has clinical benefit when compared with paclitaxel/carboplatin alone in patients with previously untreated lung cancer.
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00527735
- Testing
- Ipilimumab, Paclitaxel, Carboplatin
- Where
- 72 sites in United States, France and 6 more
- Volunteers
- 334 people
- Sponsor
- Bristol-Myers Squibb
Melanoma, Non Small Cell Lung Cancer
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN)…
- Trial name
- NCT02381314
- Testing
- enoblituzumab plus ipilimumab
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- MacroGenics
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal…
- Trial name
- NCT02231749
- Testing
- Nivolumab, Ipilimumab, Sunitinib
- Where
- 189 sites in United States, Argentina and 26 more
- Volunteers
- 1,096 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
The purpose of this study is to evaluate the safety and effectiveness of Nivolumab in combination with Ipilimumab in Chinese participants with previously treated late stage cancer.
- Trial name
- NCT03195478
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in China
- Volunteers
- 37 people
- Sponsor
- Bristol-Myers Squibb
Non-Small-Cell Lung Cancer
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
The purpose of part 1 of this study is to determine the objective response rate (ORR) in stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy.
- Trial name
- CheckMate 568 (NCT02659059)
- Testing
- Nivolumab, Ipilimumab, Platinum Doublet Chemotherapy
- Where
- 32 sites in United States, Canada
- Volunteers
- 324 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
- Trial name
- FRACTION-RCC (NCT02996110)
- Testing
- Nivolumab, Ipilimumab, Relatlimab
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 182 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a…
- Trial name
- NCT01057810
- Testing
- Ipilimumab
- Where
- 134 sites in United States, Argentina and 22 more
- Volunteers
- 837 people
- Sponsor
- Bristol-Myers Squibb